Variability of Patterns of Fatigue and Quality of Life Over Time Based on Different Breast Cancer Adjuvant Chemotherapy Regimens

Ann M. Berger

Kari Lockhart

Sangeeta Agrawal

fatigue, quality of life
ONF 2009, 36(5), 563-570. DOI: 10.1188/09.ONF.563-570

Purpose/Objectives: To examine the relationships among fatigue and physical and mental quality of life (QOL) and different adjuvant chemotherapy regimens in patients with stage I-IIIA breast cancer prior to, during, and after treatment.

Design: Longitudinal, descriptive design embedded in a randomized, clinical trial.

Setting: Outpatient oncology clinics in the midwestern United States.

Sample: 196 postoperative women, mean age of 52 years, receiving anthracycline-based chemotherapy regimens: dose-dense taxane, dose-standard taxane, or dose-standard without taxane.

Methods: The Piper Fatigue Scale and Medical Outcomes Study SF-36® (v.2) Survey were completed 48 hours prior to treatment 1, at treatments 4 and 8, and 30 days after the final treatment.

Main Research Variables: Fatigue, adjuvant chemotherapy regimen, and QOL.

Findings: Fatigue and mental QOL changed significantly over time for all regimens, but the patterns of change did not differ based on regimen. Physical QOL changed significantly over time for all regimens, and the pattern of change differed based on whether taxanes were received. Higher fatigue was correlated with lower physical and mental QOL prior to and 30 days after the final treatment, regardless of regimen.

Conclusions: Women who receive taxanes are at higher risk for lower physical QOL over time. Higher fatigue was associated with lower QOL regardless of the chemotherapy regimens.

Implications for Nursing: Clinicians should screen patients for fatigue and assess for contributing factors at clinic visits. Methods to integrate evidence-based fatigue interventions into practice should be tested and outcomes evaluated.

Jump to a section


    American Cancer Society. (2007). Cancer facts and figures 2007. Retrieved September 22, 2007, from
    American Cancer Society. (2009). Cancer facts and figures 2009. Retrieved July 27, 2009, from
    Andrykowski, M.A., Schmidt, J.E., Salsman, J.M., Beacham, A.O., & Jacobsen, P.B. (2005). Use of a case definition approach to identify cancer-related fatigue in women undergoing adjuvant therapy for breast cancer. Journal of Clinical Oncology, 23(27), 6613-6622.
    Avis, N.E., Crawford, S., & Manuel, J. (2005). QOL among younger women with breast cancer. Journal of Clinical Oncology, 23(15), 3322-3330.
    Banthia, R., Malcarne, V.L., Roesch, S.C., Ko, C.M., Greenbergs, H.L., Varni, J.W., et al. (2006). Correspondence between fatigue reports in breast cancer survivors. Journal of Behavioral Medicine, 29(3), 269-279.
    Berger, A.M., Kuhn, B.R., Farr, L.A., Lynch, J.C., Agrawal, S., Chamberlain, J., et al. (2009). Behavioral therapy intervention trial to improve sleep quality and cancer-related fatigue. Psycho-Oncology, 18(6), 634-646.
    Berger, A.M., Sankaranarayanan, J., & Watanabe-Galloway, S. (2007). Current methodological approaches to the study of sleep disturbances and QOL in adults with cancer. Psycho-Oncology, 16(5), 401-420.
    Box, B.A., & Russell, C.A. (2004). Breast cancer. In D.A. Casciato (Ed.), Manual of clinical oncology (5th ed., pp. 233-253). Philadelphia: Lippincott Williams and Wilkins.
    Byar, K.L., Berger, A.M., Bakken, S.L., & Cetak, M.A. (2006). Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life [Online exclusive]. Oncology Nursing Forum, 33(1), E18-E26. Retrieved July 20, 2009, from
    Cleeland, C.S., Mendoza, T.R., Wang, X.S., Chou, C., Harle, M.T., Morrissey, M., et al. (2000). Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer, 7(89), 1634-1646.
    de Jong, N., Courtens, A.M., Abu-Saad, H.H., & Schouten, H.C. (2002). Fatigue in patients with breast cancer receiving adjuvant chemotherapy. Cancer Nursing, 25(4), 283-297.
    Haghighat, S., Akbari, M.E., Holakouei, K., Rahimi, A., & Montazeri, A. (2003). Factors predicting fatigue in breast cancer patients. Supportive Care in Cancer, 11(8), 533-538.
    Heidrich, S.M., Egan, J.J., Hengudomsub, P., & Randolph, S.M. (2006). Symptoms, symptom beliefs, and quality of life of older breast cancer survivors. Oncology Nursing Forum, 33(2), 315-322.
    Martin, M., Lluch, A., Segui, M.A., Ruiz, A., Ramos, M., Adrover, E., et al. (2006). Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Annals of Oncology, 17(8), 1205-1212.
    Mills, P.J., Parker, B., Dimsdale, J.E., Robins-Sadler, G.R., & Ancoli-Israel, S. (2005). The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biological Psychology, 69(1), 85-96.
    Mitchell, S.A., Beck, S.L., Hood, L.E., Moore, K., & Tanner, E.R. (2007). Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. Clinical Journal of Oncology Nursing, 11(1), 99-113.
    Moulder, S., & Hortobagyi, G.N. (2008). Advances in the treatment of breast cancer. Clinical Pharmacology and Therapeutics, 83(1), 26-36.
    National Comprehensive Cancer Network. (2008a). NCCN Clinical Practice Guidelines in Oncology™: Cancer-related fatigue [v.1.08]. Retrieved February 23, 2008, from
    National Comprehensive Cancer Network. (2008b). NCCN Clinical Practice Guidelines in Oncology™: Invasive breast cancer [v.1.08]. Retrieved September 4, 2008, from
    Piper, B.F., Dibble, S.L., Dodd, M.J., Weiss, M.C., Slaughter, R.E., & Paul, S.M. (1998). The Revised Piper Fatigue Scale: Psychometric evaluation in women with breast cancer. Oncology Nursing Forum, 25(4), 677-684.
    Piper, B.F., Lindsey, A.M., & Dodd, M.J. (1987). Fatigue mechanisms in cancer patients. Oncology Nursing Forum, 14(6), 17-23.
    Prue, G., Rankin, J., Allen, J., Gracey, J., & Cramp, F. (2006). Cancer-related fatigue: A critical appraisal. European Journal of Cancer, 42(7), 846-863.
    Sura, W., Murphy, S.O., & Gonzales, I. (2006). Level of fatigue in women receiving dose-dense versus standard chemotherapy for breast cancer: A pilot study. Oncology Nursing Forum, 33(5), 1015-1021.
    Ware, J.E. (2000). SF-36 Health Survey. Spine, 25(24), 3130-3139.
    Wielgus, K.K., Berger, A.M., & Hertzog, M. (2009). Predictors of fatigue 30 days after completing anthracycline plus taxane adjuvant chemotherapy. Oncology Nursing Forum, 36(1), 38-48.
    Wildiers, H., Dirix, L., Neven, P., Prove, A., Clement, P., Squifflet, P., et al. (2009). Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment. Breast Cancer Treatment Research, 114(1), 103-112.
    Woo, B., Dibble, S.L., Piper, B.F., Keating, S.B., & Weiss, M.C. (1998). Differences in fatigue by treatment methods in women with breast cancer. Oncology Nursing Forum, 25(5), 915-920.